The U.S. Supreme Court handed Hikma Pharmaceuticals and the generic industry a decisive win in a “skinny label” patent dispute tied to a prescription-strength fish oil product. In a unanimous decision, the Court rejected theories that would have expanded infringement for knockoff products that rely on carve-outs from covered labeling, preserving the viability of skinny-label challenges. The ruling was issued in a case closely watched by generic manufacturers and branded drugmakers because it directly impacts how “induced infringement” arguments can be applied to partial-label products. The decision also reinforces a practical pathway for generic entry when patent protections don’t extend to the non-covered dosing. For industry stakeholders, the effect is immediate: companies will reassess patent-risk models around labeling strategies and design future paragraph-IV-style positions accordingly, while branded firms will face greater scrutiny on the scope of their patent hooks. Overall, the Court’s action reduces legal uncertainty surrounding skinny labels, which are a cornerstone mechanism for faster generic competition in the U.S.